Artizan Biosciences has entered into a multi-year research collaboration with the University Medical Center Utrecht in The Netherlands and Microviable Therapeutics SL to explore the role that gut microbiota may have in immune checkpoint inhibitor (“ICI”) therapies for patients with cancer.
“We are excited by the potential of this collaboration to showcase the diversity of Artizan’s unique technology platform and to further expand our pipeline into oncology,” said Bridget Martell, M.A., M.D., Artizan’s President and CEO.